News & Events
News & Events
Institut Pasteur Korea - KaiPharm Join to Establish an AI-driven First-in-class Drug Discovery Platform
2019-08-07
Institut Pasteur Korea – KaiPharm Join to Establish an AI-driven First-in-class Drug Discovery Platform
- Increasing possibilities for identification of new mechanism of action and target, prediction of drug activity and repositioning of existing drugs –
August 7, 2019, Gyeonggi Province, Rep. of Korea | Institut Pasteur Korea (CEO: Wang-shick Ryu) and KaiPharm (CEO: Wan-kyu Kim) signed on a joint research agreement to generate an NGS-driven drug-induced transcriptome database (KMAP project).
.jpg)
The goal of KMAP project is to establish a standard database(KMAP) of drug-induced transcriptome that can be referred for new therapeutic development. KMAP is to be built as a reference transcriptome database for thousands of drugs generated by next generation sequencing (NGS), and will be able to provide more comprehensive understanding of drug mechanism of action.
Drug treatments affect the expression of 10s~1,000s of genes in cells, resulting in drug-specific patterns of gene expression. A standard database of drug-induced transcriptome for various drugs can be used to trace existing drugs of similar transcriptome patterns, or to infer novel indications.
As a first step of this joint project, the Institut Pasteur Korea will perform an automated high throughput screening of the cells treated with about 2,000 drugs, mostly US FDA-approved drugs, and produce NGS sequencing libraries. KaiPharm will build a standard database of drug-induced transcriptomes, and develop algorithms that can help interpret the drug’s mechanism of action and predict their targets or indications.
Based on a jointly established standard database, or KMAP, the two organizations are planning to provide a global technology platform service for domestic and international pharmaceutical companies to help with the creation of new drugs, anticipation of side effects and toxicity, selection of lead compounds, and prediction of natural product activity.
- Increasing possibilities for identification of new mechanism of action and target, prediction of drug activity and repositioning of existing drugs –
August 7, 2019, Gyeonggi Province, Rep. of Korea | Institut Pasteur Korea (CEO: Wang-shick Ryu) and KaiPharm (CEO: Wan-kyu Kim) signed on a joint research agreement to generate an NGS-driven drug-induced transcriptome database (KMAP project).
The goal of KMAP project is to establish a standard database(KMAP) of drug-induced transcriptome that can be referred for new therapeutic development. KMAP is to be built as a reference transcriptome database for thousands of drugs generated by next generation sequencing (NGS), and will be able to provide more comprehensive understanding of drug mechanism of action.
Drug treatments affect the expression of 10s~1,000s of genes in cells, resulting in drug-specific patterns of gene expression. A standard database of drug-induced transcriptome for various drugs can be used to trace existing drugs of similar transcriptome patterns, or to infer novel indications.
As a first step of this joint project, the Institut Pasteur Korea will perform an automated high throughput screening of the cells treated with about 2,000 drugs, mostly US FDA-approved drugs, and produce NGS sequencing libraries. KaiPharm will build a standard database of drug-induced transcriptomes, and develop algorithms that can help interpret the drug’s mechanism of action and predict their targets or indications.
Based on a jointly established standard database, or KMAP, the two organizations are planning to provide a global technology platform service for domestic and international pharmaceutical companies to help with the creation of new drugs, anticipation of side effects and toxicity, selection of lead compounds, and prediction of natural product activity.
Dr. Wang-shick Ryu, the CEO of Institut Pasteur Korea, said, “KaiPharm is a leading biotech with a unique technology in transcriptome analysis and big data mining. This collaboration will provide a door to elucidate novel mechanism of actions or targets of the previously approved drugs, which can be translated to the first-in-class drugs discovery research.”
Prof. Wan-kyu Kim, the CEO of KaiPharm, expressed, “The high throughput screening and cell imaging technology and infrastructure of Institut Pasteur Korea is world-class. With the synergy from the partnership, we will be able to establish and provide an innovative technology platform facilitating drug discovery.
Leveraging the state-of-the-art drug development technology platform, Institut Pasteur Korea has been focusing on drug discovery in the field of infectious diseases, including TB, super bacteria, and emerging viruses.
Founded in 2018 by Prof. Wan-kyu Kim of the Ewha Womans University, KaiPharm is a biotech company advancing the next generation drug discovery research using the unique big data mining technologies and virtual screening algorithms.
Leveraging the state-of-the-art drug development technology platform, Institut Pasteur Korea has been focusing on drug discovery in the field of infectious diseases, including TB, super bacteria, and emerging viruses.
Founded in 2018 by Prof. Wan-kyu Kim of the Ewha Womans University, KaiPharm is a biotech company advancing the next generation drug discovery research using the unique big data mining technologies and virtual screening algorithms.